King Pharmaceuticals KG Program Services — Restricted Cash and Investments

Other segment segments

Legacy Reinsurance

$159.5M—

Similar metrics at other companies

STWDInvesting and Servicing Segment — Restricted Cash

$412K—

SLMRestricted Cash and Investments

$223.92M+29.1%

KBHFinancial services — Restricted Cash

$900K-30.8%

RYNRestricted Cash and Investments

$495K-26.9%

BBRestricted Cash and Investments

$14.2M-13.9%

HOVFinancial Services — Restricted Cash And Cash Equivalents

$24.5M-22.2%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's program services — restricted cash and investments.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's program services — restricted cash and investments?: King Pharmaceuticals (KG) reported program services — restricted cash and investments of $2.59M in Q1 2026.
What does program services — restricted cash and investments mean?: This represents cash and investment balances within the Program Services segment that are not available for general corporate use due to regulatory, contractual, or legal requirements. These assets are typically held to satisfy collateral obligations or statutory reserve mandates. It is a key indicator of the segment's liquidity constraints and regulatory compliance status.